Biden Administration Awards $500M for New COVID Treatments

The Department of Health and Human Services (HHS) on Friday announced it is awarding $500 million in grants to support the development of future COVID-19 vaccines and therapeutics.

The funds were granted through the Administration for Strategic Preparedness and Response (ASPR) as part of the federal government’s Project NextGen, which aims to enhance preparedness against future COVID-19 variants. HHS awarded $1.4 billion in grants through the same program earlier this year.

Among the recipients were the developers of two intranasal vaccine candidates: CastleVax and Codagenix. They were awarded $8.5 million and $10 million respectively.

Intranasal vaccines are rare but not unheard of. In the U.S., the spray flu vaccine called FluMist is approved for people aged two to 49.

...Unlike the more common mRNA COVID-19 vaccines, the intranasal candidate from Codagenix is more traditional in that is uses a modified, weakened version of the virus to induce an immune response

“CoviLiv can induce a robust, systemic immune response after intranasal delivery of this live attenuated bio-vaccine,” Kaufman said, adding that her company’s vaccine induced a response that not only targeted spike proteins — as mRNA vaccines do — but also other viral proteins that mutate less.

SOURCE: The Hill (https://news.yahoo.com/biden-administration-awards-500m-covid-201637271.html)
#news #covid19 #vaccine #vaccines #covidvaccine
Biden Administration Awards $500M for New COVID Treatments The Department of Health and Human Services (HHS) on Friday announced it is awarding $500 million in grants to support the development of future COVID-19 vaccines and therapeutics. The funds were granted through the Administration for Strategic Preparedness and Response (ASPR) as part of the federal government’s Project NextGen, which aims to enhance preparedness against future COVID-19 variants. HHS awarded $1.4 billion in grants through the same program earlier this year. Among the recipients were the developers of two intranasal vaccine candidates: CastleVax and Codagenix. They were awarded $8.5 million and $10 million respectively. Intranasal vaccines are rare but not unheard of. In the U.S., the spray flu vaccine called FluMist is approved for people aged two to 49. ...Unlike the more common mRNA COVID-19 vaccines, the intranasal candidate from Codagenix is more traditional in that is uses a modified, weakened version of the virus to induce an immune response “CoviLiv can induce a robust, systemic immune response after intranasal delivery of this live attenuated bio-vaccine,” Kaufman said, adding that her company’s vaccine induced a response that not only targeted spike proteins — as mRNA vaccines do — but also other viral proteins that mutate less. SOURCE: The Hill (https://news.yahoo.com/biden-administration-awards-500m-covid-201637271.html) #news #covid19 #vaccine #vaccines #covidvaccine
NEWS.YAHOO.COM
Biden administration awards $500M for new COVID treatments
The Department of Health and Human Services (HHS) on Friday announced it is awarding $500 million in grants to support the development of future COVID-19 vaccines and therapeutics. The funds were granted through the Administration for Strategic Preparedness and Response (ASPR) as part of the federal government’s Project NextGen, which aims to enhance preparedness against…
0 Comments 0 Shares 4760 Views